Bevacizumab biosimilar - Boehringer Ingelheim

Drug Profile

Bevacizumab biosimilar - Boehringer Ingelheim

Alternative Names: BI 695502

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Boehringer Ingelheim
  • Class Antineoplastics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Colorectal cancer; Non-small cell lung cancer
  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Cancer(In volunteers) in New Zealand (IV, Infusion)
  • 01 Jun 2016 Phase-III clinical trials in Colorectal cancer (Metastatic disease, First-line therapy, Combination therapy) in Japan, Spain (IV) (NCT02776683)
  • 01 Jul 2015 Phase-III clinical trials in Non-small cell lung cancer (Combination therapy, First-line therapy, Recurrent, Late-stage disease, Metastatic disease) in Argentina, Germany, Portugal (IV) (NCT02272413)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top